Söndag 13 September | 18:28:30 Europe / Stockholm
Est. tid*
2026-08-31 - Kvartalsrapport 2026-Q2
2026-06-28 - Årsstämma
2026-06-26 - Årsstämma
2026-05-28 - Kvartalsrapport 2026-Q1
2026-05-08 - X-dag ordinarie utdelning MEDFIN B 0.00 SEK
2026-04-28 - Extra Bolagsstämma 2026
2026-02-20 - Bokslutskommuniké 2025
2025-11-27 - Kvartalsrapport 2025-Q3
2025-08-28 - Kvartalsrapport 2025-Q2
2025-06-26 - Årsstämma
2025-05-28 - Kvartalsrapport 2025-Q1
2025-05-09 - X-dag ordinarie utdelning MEDFIN B 0.00 SEK
2025-02-27 - Bokslutskommuniké 2024
2024-11-28 - Kvartalsrapport 2024-Q3
2024-09-24 - Split MEDFIN B 400:1
2024-08-29 - Kvartalsrapport 2024-Q2
2024-06-28 - X-dag ordinarie utdelning MEDFIN B 0.00 SEK
2024-06-27 - Årsstämma
2024-05-28 - Kvartalsrapport 2024-Q1
2024-03-01 - Extra Bolagsstämma 2024
2024-02-22 - Bokslutskommuniké 2023
2023-11-30 - Kvartalsrapport 2023-Q3
2023-08-31 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning MEDFIN B 0.00 SEK
2023-05-25 - Årsstämma
2023-05-17 - Kvartalsrapport 2023-Q1
2023-02-22 - Bokslutskommuniké 2022
2022-11-30 - Kvartalsrapport 2022-Q3
2022-08-31 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning MEDFIN B 0.00 SEK
2022-05-18 - Kvartalsrapport 2022-Q1
2022-03-01 - Split MEDFIN B 1:10
2022-02-24 - Bokslutskommuniké 2021
2022-02-14 - Extra Bolagsstämma 2022
2021-11-18 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-06-03 - X-dag ordinarie utdelning MEDFIN B 0.00 SEK
2021-06-02 - Årsstämma
2021-05-20 - Kvartalsrapport 2021-Q1
2021-02-17 - Bokslutskommuniké 2020
2020-11-26 - Kvartalsrapport 2020-Q3
2020-08-26 - Kvartalsrapport 2020-Q2
2020-06-04 - X-dag ordinarie utdelning MEDFIN B 0.00 SEK
2020-06-03 - Årsstämma
2020-05-21 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-11-28 - Kvartalsrapport 2019-Q3
2019-08-29 - Kvartalsrapport 2019-Q2
2019-06-25 - X-dag ordinarie utdelning MEDFIN B 0.00 SEK
2019-05-28 - Årsstämma
2019-05-22 - Kvartalsrapport 2019-Q1
2019-02-20 - Bokslutskommuniké 2018
2018-08-28 - Kvartalsrapport 2018-Q2
2018-05-25 - X-dag ordinarie utdelning MEDFIN B 0.00 SEK
2018-05-24 - Årsstämma
2018-05-21 - Kvartalsrapport 2018-Q1
2018-01-22 - Bokslutskommuniké 2017
LandSverige
ListaNordic SME Sweden
SektorHandel & varor
IndustriDagligvaror
Medicortex International är ett medicinteknikbolag som utvecklar diagnostiska lösningar för traumatiska hjärnskador, med fokus på biomarkörbaserade tester. Bolaget bedriver forskning och utveckling med målet att möjliggöra snabb och tillgänglig diagnostik samt arbetar långsiktigt med utveckling av behandlingslösningar. Verksamheten har en internationell inriktning.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Medicortex International AB (publ) enters into agreements ahead of planned directed set-off share issues totalling approximately SEK 9.9 million

2026-09-01 13:48:00

Settlement of a loan, a fee for expanding the shareholder base, and a consultancy receivable through newly issued shares

Medicortex International AB (publ) (“Medicortex” or “the Company”) announces today that the Company has entered into agreements with NoteCom Holding AB (publ) and Dividend Sweden AB, respectively, ahead of two planned directed share issues against set-off of receivables. The planned issues are intended to comprise a total of approximately SEK 9,943,850 through the set-off of receivables, without any cash contribution. The intended subscription price per share is SEK 1.30 in both issues.

Background and rationale

In connection with the Company’s reverse acquisition of Medicortex Finland Oyj in March 2026, NoteCom Invest AB provided an interest-free bridge loan of SEK 4,000,000 to the then Nosium AB (publ), in order to ensure that the Company’s capital base was sufficient ahead of Nordic Growth Market’s (NGM) approval of the reverse acquisition. Under the loan agreement and a subsequent supplemental agreement, the loan was not to be repaid in cash but was to be settled through a set-off share issue following completion of the acquisition.

NoteCom Invest AB has since assigned the loan receivable to NoteCom Holding AB (publ). The Company and NoteCom Holding AB (publ) have further entered into an agreement regarding an assignment to expand the Company’s shareholder base, under which NoteCom Holding AB (publ) shall plan, structure and administer a broadening of the shareholder base, including making available its distribution structure and existing shareholder base for this purpose. As consideration for the assignment, NoteCom Holding AB (publ) will receive SEK 4,840,000. Part of the consideration is intended to be used to distribute shares to new shareholders as part of the broadening of the Company’s shareholder base. The consideration is not conditional on the distribution of shares having actually been completed at the time of subscription.

The assumed loan receivable of SEK 4,000,000 and the consideration of SEK 4,840,000, together SEK 8,840,000, are intended to be set off in full against the Company’s receivable from NoteCom Holding AB (publ) for subscription of new shares.

In addition, the Company has entered into an agreement with Dividend Sweden AB regarding substitution of debtor and set-off in respect of a consultancy fee, originally invoiced to Medicortex Finland Oyj in the amount of EUR 100,000 for services in connection with the reverse acquisition. The receivable has been converted into Swedish kronor at the European Central Bank’s (ECB) reference rate of 19 August 2026 (EUR 1.00 = SEK 11.0385) and amounts, following conversion, to SEK 1,103,850. Of this amount, SEK 1,103,849.50 is intended to be set off against new shares; the remaining SEK 0.50 is waived.

Planned set-off issues in summary

CounterpartyNumber of new sharesSubscription priceAmount set off
NoteCom Holding AB (publ)6,800,000SEK 1.30SEK 8,840,000
Dividend Sweden AB849,115SEK 1.30SEK 1,103,849.50
Total7,649,115SEK 9,943,849.50

Upon completion of the issues, the total number of shares and votes in the Company will increase by 7,649,115, from 23,333,909 to 30,983,024 shares. This corresponds to a dilution of approximately 24.7 percent of the shares and votes for shareholders not participating in the issues.

Conditions for completion

Completion of each set-off issue is subject to the requisite corporate resolutions being adopted and the issues being registered with the Swedish Companies Registration Office (Bolagsverket). Until then, the receivables remain as monetary claims against the Company.